Summit

SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools
 

Concept

Diabetes mellitus is a lifelong, incapacitating disease affecting multiple organs. Worldwide prevalence figures estimate that there are 250 million diabetic patients today and that this number will increase by 50% by 2025 (1). Presently, diabetes can diabetes type 1 and type 2 cannot be cured and only partially (type 2) prevented. The disease is associated with devastating chronic complications including coronary heart disease, stroke and peripheral vascular disease (macrovascular disease) as well as microvascular disorders leading to damage of kidneys (nephropathy) and eyes (retinopathy). These complications impose an immense burden on the quality of life of the patients and account for more than 10% of health care costs in Europe (2). Therefore, novel means to prevent and/or treat these devastating diabetic complications are needed. An important step would be to develop surrogate markers, which would make development of novel drugs for prevention of these complications more feasible. Although hyperglycemia represents one of the most important risk factors for development of diabetic vascular complications, not all hyperglycemic patients seem to be at equal risk: other factors clearly modify an individual’s susceptibility to develop complications.

 

Objectives

The central goal of the SUMMIT project will be to develop surrogate markers for micro- and macrovascular hard endpoints, to shorten clinical trials on diabetes. The identification and characterization of the most important risk factors for development of vascular diabetic complications can be used to predict risk and monitor the effect of interventions.

The specific objectives are:

  • to identify novel genetic markers and biomarkers which can be used for prediction and monitoring the development of diabetic vascular complications,

  • to develop novel and improve existing imaging techniques for monitoring the progress of the atherosclerotic process,

  • to develop novel animal models for vascular complications and 5) to develop novel in silico methods for predicting chronic diabetic complications.

 

Funding

IMI Research Programme - EC 7° Framework Programme

 

Duration

SUMMIT project will last 48 months, from 01/11/2009 to 31/10/2014

 

To the Official Summit Site